Trial Profile

Phase I Study of HC-7366 for Acute Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HC-7366 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions

Most Recent Events

20 Jan 2025 Protocol has been amended to remove venetoclax and azacitidine and changed this combination trial (HC-7366 plus azacitidine and venetoclax) to HC-3766 single agent study.
28 May 2024 According to a HiberCell media release, Dr. Abhishek Maiti is the principal investigator of this study.
28 May 2024 According to a HiberCell media release, company announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com